CERO THERAPEUTICS HOLDINGS, INC. Quarterly Operating Income (Loss) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cero Therapeutics Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2022 to Q2 2024.
  • Cero Therapeutics Holdings, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$5.15M, a 113% decline year-over-year.
  • Cero Therapeutics Holdings, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$10.1M.
  • Cero Therapeutics Holdings, Inc. annual Operating Income (Loss) for 2023 was -$2.93M, a 0.95% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$10.1M -$5.15M -$2.73M -113% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$7.4M -$3.65M -$1.22M -49.9% Feb 14, 2024 Mar 31, 2024 10-Q 2024-05-17
Q4 2023 -$897K Jan 1, 2024 Feb 13, 2024 10-Q 2024-08-14
Q3 2023 -$430K +$407K +48.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$2.41M -$2.04M -541% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$2.44M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q3 2022 -$837K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$377K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.